ロード中...
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
BACKGROUND: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering diffe...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8010824/ https://ncbi.nlm.nih.gov/pubmed/33854567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211002720 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|